| COVID-19 |
1 |
1 |
| Biliary Disease |
0 |
0.99 |
| Metabolic Syndrome |
0 |
0.98 |
| Non-Alcoholic Fatty Liver Disease |
0 |
0.97 |
| Fatty Liver |
0 |
0.9 |
| Liver |
0 |
0.79 |
| Liver Disease |
0 |
0.75 |
| Aminotransferase |
0 |
0.6 |
| Hepatic Fibrosis |
0 |
0.59 |
| Hepatocellular Carcinoma |
0 |
0.39 |
| Metabolism |
0 |
0.26 |
| Steatosis |
0 |
0.26 |
| Intubation |
0 |
0.22 |
| Body Mass Index |
0 |
0.13 |
| Hypertension |
0 |
0.12 |
| Obesity |
0 |
0.1 |
| Type 2 Diabetes Mellitus |
0 |
0.1 |
| Cardiovascular Risk Management |
0 |
0.09 |
| Hospital |
0 |
0.09 |
| Lipids Management |
0 |
0.09 |
| Plasma |
0 |
0.09 |
| Preventive Screening |
0 |
0.09 |
| Biologic Therapy |
0 |
0.06 |
| Coronary Artery Disease (CAD) |
0 |
0.06 |
| High Density Lipoprotein (HDL) cholesterol |
0 |
0.06 |
| Platelet Disorders |
0 |
0.06 |
| Biomarker |
0 |
0.04 |
| Blood |
0 |
0.04 |
| California |
0 |
0.04 |
| Cancer |
0 |
0.04 |
| Cardiovascular disease |
0 |
0.04 |
| Cirrhosis |
0 |
0.04 |
| Hepatitis |
0 |
0.04 |
| Interleukin |
0 |
0.04 |
| Lipoproteins |
0 |
0.04 |
| Myopathy |
0 |
0.04 |
| Pathogenesis |
0 |
0.04 |
| Platelet Count |
0 |
0.04 |
| Prediabetes |
0 |
0.04 |
| Triglycerides |
0 |
0.04 |
| Thrombocytopenia |
0 |
0.03 |